Want to see IN:LINCOLN full AI Analyst Report?
LINCOLN Stock Chart & Stats
₹496.60
-₹14.55(-1.74%)
At close: 4:00 PM EST
₹496.60
-₹14.55(-1.74%)
Day’s Range― - ―
52-Week Range₹439.95 - ₹770.00
Previous CloseN/A
Volume57.32K
Average Volume (3M)1.66K
Market Cap
₹12.42B
Enterprise Value₹12.33B
Total Cash (Recent Filing)₹2.32B
Total Debt (Recent Filing)₹668.00K
Price to Earnings (P/E)14.2
Beta1.10
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.37%
Share Statistics
EPS (TTM)39.95
Shares Outstanding20,029,728
10 Day Avg. Volume3,133
30 Day Avg. Volume1,664
Financial Highlights & Ratios
PEG Ratio1.91
Price to Book (P/B)1.49
Price to Sales (P/S)1.69
P/FCF Ratio13.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)72
Revenue Forecast (FY)₹8.82B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetDebt-to-equity of ~0.006 and a large equity base provide durable financial flexibility. Low leverage reduces refinancing and interest-rate risk, supports capex, M&A or downturn resilience, and meaningfully lowers bankruptcy risk versus peers with higher debt profiles.
Improved Cash GenerationA meaningful step-up in operating cash flow and FCF that covers ~76% of earnings strengthens the firm's ability to fund reinvestment, pay down liabilities or return capital. Consistent cash conversion underpins sustainable operations and long-term strategic optionality.
Steady Revenue And Healthy MarginsAccelerating revenue growth with a ~13.1% net margin indicates stable demand and profitable core operations. This combination suggests a resilient business model and product mix that can sustain cash generation and support mid-term reinvestment or margin recovery efforts.
Bears Say
Margin CompressionNotable compression across gross, operating and EBITDA margins signals structural pressure from higher input costs or weaker product mix. If persistent, this erodes operating leverage, limits reinvestment capacity and could cap long-term profit expansion absent pricing power or cost actions.
Volatile Cash ConversionHistory of uneven cash conversion and operating cash flow trailing net income exposes the company to working-capital swings. Structural variability in cash conversion can constrain sustained capex, dividends or M&A and increases sensitivity to shortfalls in collections or inventory turns.
Declining Return On EquityROE falling to 11.6% from mid-teens historically implies capital is delivering lower incremental returns. This suggests either recent investments are lower-yielding or profitability isn't scaling with equity growth, which can pressure long-term shareholder returns unless efficiency improves.
Lincoln Pharmaceuticals Ltd News
LINCOLN FAQ
What was Lincoln Pharmaceuticals Ltd’s price range in the past 12 months?
Lincoln Pharmaceuticals Ltd lowest stock price was ₹439.95 and its highest was ₹770.00 in the past 12 months.
What is Lincoln Pharmaceuticals Ltd’s market cap?
Lincoln Pharmaceuticals Ltd’s market cap is ₹12.42B.
When is Lincoln Pharmaceuticals Ltd’s upcoming earnings report date?
Lincoln Pharmaceuticals Ltd’s upcoming earnings report date is Aug 06, 2026 which is in 31 days.
How were Lincoln Pharmaceuticals Ltd’s earnings last quarter?
Lincoln Pharmaceuticals Ltd released its earnings results on May 28, 2026. The company reported ₹5.81 earnings per share for the quarter, beating the consensus estimate of N/A by ₹5.81.
Is Lincoln Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Lincoln Pharmaceuticals Ltd’s price is currently Overvalued.
Does Lincoln Pharmaceuticals Ltd pay dividends?
Lincoln Pharmaceuticals Ltd pays a Annually dividend of ₹1.8 which represents an annual dividend yield of 0.37%. See more information on Lincoln Pharmaceuticals Ltd dividends here
What is Lincoln Pharmaceuticals Ltd’s EPS estimate?
Lincoln Pharmaceuticals Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lincoln Pharmaceuticals Ltd have?
Lincoln Pharmaceuticals Ltd has 20,029,728 shares outstanding.
What happened to Lincoln Pharmaceuticals Ltd’s price movement after its last earnings report?
Lincoln Pharmaceuticals Ltd reported an EPS of ₹5.81 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lincoln Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in IN:LINCOLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Limited, established in 1979 and headquartered in Ahmedabad, India, is a pharmaceutical company engaged in the manufacturing and global distribution of its products. Its comprehensive product line addresses a wide array of medical needs, including dermatological, gynecological, gastrointestinal, and otological conditions. The company also specializes in phosphodiesterase type 5 inhibitors and general anesthetics. Further expanding its therapeutic reach, Lincoln provides treatments for common ailments like coughs, colds, and allergies, alongside anti-asthmatics. Other key product categories include sterile ophthalmic solutions (eye drops and ointments), anti-malarial drugs, and a range of vitamins, minerals, and antioxidants. The portfolio is further diversified with anti-bacterial, anti-viral, and anti-fungal agents; pain relief and fever reduction medications (analgesics and anti-pyretics); and specialized drugs for mental health (anti-psychotics, anti-convulsants, anti-depressants) and diabetes (anti-diabetics). Cardiovascular health is addressed with anti-hypertensives and diuretics, while gastrointestinal issues are targeted with anti-diarrheals, anti-spasmodics, and laxatives. Additionally, the company offers branded generic pharmaceuticals.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Jagsonpal Pharmaceuticals Ltd.
―
Syncom Formulation (India) Ltd.
―
Venus Remedies Limited
―
Wanbury Limited
―